Stock Ratings / Health Care / SBFM / insiders

APVO (46) PRFX (39) HCWB (27) SILO (19) ⌘ Pro Terminal →

Sunshine Biopharma Inc. (SBFM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are SBFM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SBFM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$3.33 +7.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Sunshine Biopharma Inc. (SBFM) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SBFM)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

SBFM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (SBFM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on SBFM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SBFM)

✓Walkthrough of SBFM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SBFM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.27%⚡ TESTING RESISTANCE

2026-10-30O $3.10H $3.33L $2.65C $3.33VOL 112.3K

RES: $34.13SUP: $0.90SMA50: $14.16SMA200: $109.1

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SBFM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SBFM Butterfly Map → + Track SBFM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +4.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SBFM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SBFM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SBFM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SBFM)

Health Care Rank #531 of 1016 ⚔️ APVO vs SBFM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SBFM vs. APVO, PRFX, HCWB, SILO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sunshine Biopharma Inc. (SBFM) ranks #531 by composite RQD confidence (44/100, grade D) and #986 by equity capitalization ($2.5M). Within this direct 5-issuer industry benchmark cohort, SBFM leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SBFM at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SBFM ACTIVE Sunshine Biopharma Inc.	D	44/100	—	33.8%	-21.4%	+7.07%	$2.5M	Benchmark Subject
APVO Aptevo Therapeutics Inc.	D	46/100	—	—	-35.0%	+4.62%	$2.5M	/apvo-vs-sbfm →
PRFX PRF Technologies Ltd.	D-	39/100	—	-30.0%	-35.0%	-3.86%	$2.6M	/prfx-vs-sbfm →
HCWB HCW Biologics Inc.	E	27/100	—	20.0%	-35.0%	-3.28%	$2.6M	/hcwb-vs-sbfm →
SILO Silo Pharma Inc.	E	19/100	—	38.6%	-35.0%	-6.72%	$2.4M	/silo-vs-sbfm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001402328

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sunshine Biopharma Inc. (SBFM) reported GAAP revenue of $36.3M (+4.1% vs. FY2024 revenue of $34.9M , and +50.7% cumulative change since FY2023) , GAAP net income of -$6.0M, operating cash flow of -$5.3M, and free cash flow of -$5.5M (+61.2% YoY). On the balance sheet, SBFM closed FY2025 with $30.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$36.3M	-$6.0M	-$5.3M	-$5.5M	$30.1M	—
FY2024 (FY)	2024-12-31	$34.9M	-$5.1M	-$12.5M	-$14.2M	$30.6M	—
FY2023 (FY)	2023-12-31	$24.1M	-$4.5M	-$8.8M	-$8.8M	—	—

3. SBFM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SBFM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sunshine Biopharma Inc. (NASDAQ: SBFM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.33 (+7.07% 1D, market cap $2.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SBFM ranks #531 in composite RQD confidence.

How does SBFM compare to APVO and PRFX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SBFM carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 33.8%, and ROIC of -21.4%. By comparison, APVO (Aptevo Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and PRFX (PRF Technologies Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M). Among the 5-stock peer group, SBFM leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SBFM?

Per SBFM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001402328), Sunshine Biopharma Inc. generated $36.3M in revenue (+4.1% YoY), -$6.0M in net income, and -$5.5M in free cash flow against $30.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SBFM trading relative to its 50-day, 200-day, and 52-week technical levels?

SBFM last traded at $3.33 (+7.07% on volume of 183,387 shares), positioning the stock -76.48% below its 50-day simple moving average ($14.16) and -96.95% below its 200-day simple moving average ($109.05). Across its 52-week range of $2.58 to $464.00, SBFM sits at the 0.2% percentile with a 14-day RSI of 27.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.91 to $3.75).

SBFM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are SBFM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies SBFM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: SBFM RQD Cockpit SBFM 12M Forecast SBFM Earnings & Move SBFM Dividends & DRIP SBFM Insiders & 13F SBFM Whale Options SBFM Profit Sankey SBFM News & Why